See the DrugPatentWatch profile for Onivyde
Onivyde is manufactured by Ipsen Biopharmaceuticals [1]. Ipsen acquired the rights to Onivyde from Merrimack Pharmaceuticals in 2021 [2].
What is Onivyde used to treat?
Onivyde is a liposomal formulation of irinotecan used in combination with fluorouracil and leucovorin to treat patients with metastatic adenocarcinoma of the pancreas [3]. It is indicated after disease progression following gemcitabine-based chemotherapy [3].
How does Onivyde work?
Onivyde works by delivering a higher concentration of the active chemotherapy drug, irinotecan, to the tumor. The liposomal encapsulation of irinotecan helps it accumulate in tumor tissue, potentially enhancing its efficacy and reducing systemic toxicity compared to conventional irinotecan [4].
When did Onivyde receive FDA approval?
The U.S. Food and Drug Administration (FDA) approved Onivyde in October 2015 [3].
What is the patent status for Onivyde?
Information on Onivyde's patent status, including expiry dates and any ongoing patent challenges, can be found through patent databases and specialized pharmaceutical intelligence services like DrugPatentWatch.com [5]. Patent exclusivity is a key factor in determining when generic or biosimilar versions of a drug can enter the market [6].
Are there other treatments for metastatic pancreatic cancer?
Besides Onivyde, other treatments for metastatic pancreatic cancer include gemcitabine, FOLFIRINOX (a combination of fluorouracil, leucovorin, irinotecan, and oxaliplatin), and nab-paclitaxel [7]. Treatment decisions depend on the patient's overall health, cancer stage, and prior treatments [7].